BIOMAT Database Logo BIOMAT Database Logo

Protease inhibitors and cardiovascular outcomes in patients with HIV-1. 2002

Scott D Holmberg, and Anne C Moorman, and John M Williamson, and Tony C Tong, and Douglas J Ward, and Kathy C Wood, and Alan E Greenberg, and Robert S Janssen, and
Division of HIV/AIDS Prevention, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA. sdh1@cdc.gov

Protease inhibitors for treatment of HIV-1 have been linked with increased risk of hyperlipidaemia and hyperglycaemia. In a cohort of 5672 outpatients with HIV-1 seen at nine US HIV clinics between January, 1993, and January, 2002, the frequency of myocardial infarctions increased after the introduction of protease inhibitors in 1996 (test for trend, p=0.0125). We noted that 19 of 3247 patients taking, but only two of 2425 who did not take, protease inhibitors had a myocardial infarction (odds ratio 7.1, 95% CI 1.6-44.3; Cox proportional hazards model-adjusted for smoking, sex, age, diabetes, hyperlipidaemia, and hypertension-hazard ratio 6.5, 0.9-47.8). Our findings suggest that, although infrequent, use of protease inhibitors is associated with increased risk of myocardial infarction in patients with HIV-1.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Scott D Holmberg, and Anne C Moorman, and John M Williamson, and Tony C Tong, and Douglas J Ward, and Kathy C Wood, and Alan E Greenberg, and Robert S Janssen, and
Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure.
July 2018, Journal of the American College of Cardiology,
Scott D Holmberg, and Anne C Moorman, and John M Williamson, and Tony C Tong, and Douglas J Ward, and Kathy C Wood, and Alan E Greenberg, and Robert S Janssen, and
Cardiovascular considerations in patients treated with HIV protease inhibitors.
January 2004, The Journal of the Association of Nurses in AIDS Care : JANAC,
Scott D Holmberg, and Anne C Moorman, and John M Williamson, and Tony C Tong, and Douglas J Ward, and Kathy C Wood, and Alan E Greenberg, and Robert S Janssen, and
Hyperglycemia associated with protease inhibitors in HIV-1-infected patients.
July 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
Scott D Holmberg, and Anne C Moorman, and John M Williamson, and Tony C Tong, and Douglas J Ward, and Kathy C Wood, and Alan E Greenberg, and Robert S Janssen, and
HIV-1 protease inhibitors.
June 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Scott D Holmberg, and Anne C Moorman, and John M Williamson, and Tony C Tong, and Douglas J Ward, and Kathy C Wood, and Alan E Greenberg, and Robert S Janssen, and
HIV-1 protease inhibitors.
April 2001, Drug discovery today,
Scott D Holmberg, and Anne C Moorman, and John M Williamson, and Tony C Tong, and Douglas J Ward, and Kathy C Wood, and Alan E Greenberg, and Robert S Janssen, and
HIV-1 protease inhibitors.
January 1997, AIDS clinical review,
Scott D Holmberg, and Anne C Moorman, and John M Williamson, and Tony C Tong, and Douglas J Ward, and Kathy C Wood, and Alan E Greenberg, and Robert S Janssen, and
Lipid evaluation in HIV-1-positive patients treated with protease inhibitors.
January 1999, Antiviral therapy,
Scott D Holmberg, and Anne C Moorman, and John M Williamson, and Tony C Tong, and Douglas J Ward, and Kathy C Wood, and Alan E Greenberg, and Robert S Janssen, and
Cytomegalovirus disease in HIV-1-infected patients treated with protease inhibitors.
November 1997, AIDS (London, England),
Scott D Holmberg, and Anne C Moorman, and John M Williamson, and Tony C Tong, and Douglas J Ward, and Kathy C Wood, and Alan E Greenberg, and Robert S Janssen, and
Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection.
November 1998, British journal of clinical pharmacology,
Scott D Holmberg, and Anne C Moorman, and John M Williamson, and Tony C Tong, and Douglas J Ward, and Kathy C Wood, and Alan E Greenberg, and Robert S Janssen, and
Inhibitors of HIV-1 protease.
January 1992, Journal of enzyme inhibition,
Copied contents to your clipboard!